Join us on October 8 for a lively discussion on the Telemedicine Cliff – Approaches for Navigating to the Other Side of the Public Health Emergency (PHE).
During our conversation, we will:
- Learn the high–risk areas to consider as we near the end of the PHE
- Identify how to prepare if we revert back to the pre–COVID laws
- Understand how to determine what may, or may not, change at the end of the PHE
- Forecast options for post–COVID opportunities with Telemedicine
In case you missed it, you can listen to the 3rd annual Let’s Talk Compliance program in its entirety for free, and download slides from each of the sessions, by clicking here, and be sure to check out the following Let’s Talk Compliance additional resources:
- Master Class Key Takeaways Blog
- HIPAA Breach & Penalties Webinar & Key Takeaway Blog
- Provider Relief Fund: Reporting Requirements and Compliance Concerns Webinar & Key Takeaway Blog
We are working on developing future Let’s Talk Compliance events, so stay tuned for dates and details!
People
Related Insights
December 4, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…
December 4, 2025
Foley Viewpoints
Foley Event Key Takeaways- Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shift
Foley & Lardner, Protiviti and SS&C Intralinks recently hosted an event in Foley’s Silicon Valley office at Palo Alto Center. Moderated by Foley partner Louis Lehot, the session titled "Ready for Anything: Preparing for IPOs, SPACs, and Unexpected Capital Market Shifts," brought together industry leaders: JD Fay (ex-CFO, Matterport, de-SPAC’d and then sold to CoStar Group), Dan Angus (Managing Director, Nasdaq), and Andrea Vardaro Thomas (Managing Director, Protiviti). Their combined experience provided a roadmap for companies facing the volatile and rapidly shifting capital markets of 2026.
December 4, 2025
Foley Viewpoints
FDA Guidance on Biosimilars Highlights Glycosylation Profiling and Increases the Strategic Value of Patents Covering Antibodies Defined by Glycosylation
FDA’s September 2025 guidance requires detailed characterization of posttranslational modifications (PTMs), particularly glycosylation,…